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Abstract 
Although the advent of atypical, second-generation antipsychotics (SGAs) has resulted in 
reduced likelihood of akathisia, this adverse effect remains a problem. It is known that 
extrapyramidal adverse effects are associated with increased drug occupancy of the 
dopamine 2 receptors (DRD2). The A1 allele of the DRD2/ANKK1, rs1800497, is associated 
with decreased striatal DRD2 density. The aim of this study was to identify whether the 
A1(T) allele of DRD2/ANKK1 was associated with akathisia (as measured by Barnes Akathisia 
Rating Scale) in a clinical sample of 234 patients who were treated with antipsychotic drugs. 
Definite akathisia (a score ≥ 2 in the global clinical assessment of akathisia) was significantly 
less common in subjects who were prescribed SGAs (16.8%) than those prescribed FGAs 
(47.6%), p < 0.0001. Overall, 24.1% of A1+ patients (A1A2/A1A1) who were treated with 
SGAs had akathisia, compared to 10.8% of A1(thus, A2A2) patients. A1+ patients who were 
administered SGAs also had higher global clinical assessment of akathisia scores than the 
A1subjects (p = 0.01). SGAs maintained their advantage over FGAs regarding akathisia, even 
in A1+ patients who were treated with SGAs. These results strongly suggested that A1+ 
variants of the DRD2/ANKK1 Taq1A allele do confer an associated risk for akathisia in 
patients who were treated with SGAs, and these variants may explain inconsistencies found 
across prior studies, when comparing FGAs and SGAs. 
  
Introduction 
The advent of second-generation antipsychotics (SGAs) marked a significant change in the 
pharmacotherapy of schizophrenia. The introduction of SGAs allowed many patients to 
receive antipsychotic treatment without experiencing extrapyramidal symptoms (EPS). The 
lower rate of EPS associated with SGAs resulted in the term atypical antipsychotic and a new 
class of medication was established (Kendall, 2011); however, not all patients treated with 
SGAs are free of EPS (Rummel-Kluge et al., 2010). Although these effects are often less 
pronounced (Mihanovic et al., 2010), they include: parkinsonism, tardive dyskinesia, 
dystonia and akathisia. 
Akathisia is characterised by motor restlessness and accompanying subjective distress. It 
thus has both objective and subjective components and it has been associated with suicidal 
ideation (Hansen and Kingdom, 2006; Mihanovic et al., 2010), homicidal ideation (Schulte, 
1985), diminished subjective well-being (Kim and Kim, 2009), medication non-adherence 
(Markkula et al., 2007; Perkins et al., 2002), dysphoria (Halstead et al., 1994), cognitive 
impairment (Kim and Byun, 2007) and anxiety (Hodge, 1959). Akathisia also increases the 
risk of tardive dyskinesia (Sachdev, 2004). Furthermore, worsening akathisia, anxiety and 
depression are robust predictors of antipsychotic switching (Nyhuis et al., 2010). 
  
The pathophysiological mechanisms underlying akathisia are not fully defined; however, low 
activity of dopaminergic projections from the midbrain to the ventral striatum may be 
involved (Stahl and Lonnen, 2011). Depletion of dopamine using alphamethyl-para-tyrosine 
(AMPT) (4–5 g/day) induces dysphoria and akathisia in medication-free patients with 
schizophrenia (Vorunganti and Awad, 2006). 
Positron emission tomography (PET) studies have confirmed the role of dopamine D2 
receptors (DRD2) in akathisia. Selective blockade of DRD2 by radioactive carbon-labeled 
[11C] raclopride shows induction of akathisia in both control participants and those with 
schizophrenia. The most severe symptoms occur with maximal binding of basal ganglia 
DRD2 (Farde, 1992). Individuals vary in their susceptibility for getting symptoms of akathisia, 
but hereditary factors are likely to confer risk for this disorder (Eichhammer, et al., 2000) 
and other key adverse events (Barnes et al., 2011). Because DRD2 are involved in the 
pathophysiology of akathisia, then DRD2 polymorphisms were reasonable candidates for 
possible genetic risk. Interestingly, the DRD2/ANKK 1 polymorphism was first described as 
associated with alcohol dependence disorder (Blum et al., 1990). Next, it was found that the 
carriers of the A1 allele of the DRD2/ANKK 1 Taq1A polymorphism (thus: A1/A1, A1/A2 and 
A1+) have a 30% lower DRD2 density than the non-carriers (i.e. A2/A2, A1-) (Noble, 2003). In 
vivo PET reveals that although the DRD2 availability (Bmax) is decreased in A1+ healthy 
individuals, the affinity for dopamine (Kd) is unaffected (Pohjalainen, 1998). 
ANNK1 may also influence dopaminergic neurotransmission, by affecting the 
phosphorylation of amino acid residues within the key proteins involved in dopaminergic 
activity (Munafò et al.,2007). The DRD2/ANKK 1 Taq1A polymorphism is located in a 
putative substrate binding domain of the ANNK1 gene, which results in a Glu713Lys 
substitution. This polymorphism may alter substrate-binding specificity (Neville, 2004). Most 
studies that have investigated genetic variants of the DRD2/ANKK 1 Taq1A polymorphism 
find that there is no association with EPS, in patients who were treated with first generation 
antipsychotics (FGAs) (Kaiser et al., 2002; Wu et al., 2006). Only one single study reports a 
positive association (Güzey et al., 2007). To date, any genetic studies investigating whether 
akathisia is associated with SGAs have not included the DRD2 Taq1A ANKK 1 (Dolzan et al., 
2007). Yet patients receiving antipsychotic medications do have higher prolactin levels, 
which suggests greater functional DRD2 binding in this group (Young et al., 2004). 
As the condition of akathisia is associated with maximal binding of DRD2 (Farde, 1992), our 
current study investigated whether or not A1+ patients who were treated with first or 
second generation antipsychotics were at an increased risk for akathisia. 
 
Materials and methods 
 
Participants 
We made a cross-sectional study using 234 patients between 18–65 years of age whom had 
a DSM IV diagnosis of schizophrenia and were already undergoing treatment. Because 
affective disorder diagnoses are associated with akathisia (Bratti et al., 2007) we excluded 
any participants with a current or past history of bipolar disorder, major depressive disorder 
or schizoaffective disorder. Because cognitive dysfunction is also a risk factor for akathisia 
(Bratti et al., 2007), the participants with an organic brain syndrome, dementia or epilepsy 
were excluded. 
Participants were recruited from a major community mental health centre, plus two 
inpatient units that were housed in tertiary referral teaching hospitals. Because various 
psychoactive agents can also induce akathisia (Peitl et al., 2010), we excluded patients 
taking antidepressant, opiate, anxiolytic or mood-stabilising medications. In addition, we 
excluded those taking antiemetic and antihistamine medications from our study. All 
included patients were treated with antipsychotic monotherapy, at a stable dose, for a 
minimum of 4 weeks. Participants provided informed consent prior to inclusion and were 
able to withdraw from the study at any time, without prejudice. The institutional ethics 
approvals were obtained from the clinics and hospitals involved, as well as the Queensland 
University of Technology (QUT). We followed all procedures in accordance with the ethical 
standards of these institutional ethics committees and the Declaration of Helsinki 1975, 
revised Hong Kong 1989. 
 
Assessments 
A total of 234 unrelated patients were recruited (189 males, 45 females). Of these, 191 
patients were treated with SGAs, which were prescribed as follows: 58 patients were taking 
olanzapine, 55 risperidone, 53 clozapine, 12 depot risperidone (risperdal consta), 10 
quetiapine, two were given amisulpride and one, aripiprazole. Also, 43 patients were 
treated with FGAs: 15 patients were prescribed flupenthixol decanoate, 16 zuclopenthixol 
acetate, eight received fluphenazine decanoate and four patients, haloperidol decanoate. 
For our statistical analysis, the dose of these antipsychotics was transformed to ‘mg 
chlorpromazine equivalents per kilogram’ (CPZEK). 
The average age of the study participants was 40.16 years (SD = 13.80). Ninety participants 
were inpatients and 144 were outpatients: These subjects had been diagnosed with 
schizophrenia for an average of 16.76 years (SD = 12.58). 
A clinical history was taken by one of three consultant psychiatrists, a clinical psychologist, 
or a clinical nurse. We collected demographic details, including ethnic background: 215 
patients identified themselves as Caucasian, eight as Asian, five as Polynesian or Melanesian 
(New Zealand Maori or Fijian), three as Aboriginal Australian, and three provided no 
information. Because smoking is associated with lower levels of antipsychoticinduced 
akathisia (Barnes et al., 2006), we obtained data concerning cigarette consumption. In 
addition, we obtained data pertaining to comorbid substance use, because substance abuse 
is associated with akathisia (Kumar and Sachdev, 2009). These data included: milligrams of 
nicotine consumed daily, carbon monoxide concentration expired, Alcohol Use Disorders 
Identification Test (AUDIT) scores (Babor et al., 2001) and lifetime illicit drug use. The AUDIT 
is a reliable and valid screening instrument for alcohol use disorders in people with 
schizophrenia (Dawe et al., 2000). 
All patients were administered the Barnes Akathisia Rating Scale (BARS) as outlined by 
Barnes (1989). Both the reliability and validity of this scale are well established by published 
studies (Barnes, 2003). All our study assessors were experienced mental health 
professionals with a comprehensive understanding of akathisia. All were trained in the use 
of the BARS, in order to maximise reliability (Tracy et al., 1997). All raters employed a 
standard examination procedure (Gervin and Barnes, 2000). Interrater reliability was 
ascertained in a random selection of patients. These tests were conducted at different times 
by another examiner, who was blinded to previous findings. We observed the study subjects 
in a sitting position for > 2 minutes and also whilst standing, engaged in neutral 
conversation, for at least 2 minutes as the scale instructions indicate. All ratings were 
performed blind to the genotyping data. Additionally, as negative symptoms, affective 
disorder and cognitive function are individual risk factors for akathisia, we administered the 
7-item negative scale of the Positive and Negative Syndrome Scale (PANSS) used by Kay et 
al. (1987), the General Health Questionnaire (GHQ) used by Goldberg (1972) and the Trail 
Making Test, parts A and B (Reitan,1958). 
 
Genotyping method 
We extracted DNA from blood lymphocytes, using standard techniques, and subsequently 
used it as a template for the determination of DRD2/ANNK1 genotypes. We performed 
DRD2/ ANKK1TaqIA(rs 1800479(>T)) genotyping by restriction fragment length 
polymorphism (RFLP) analysis of PCR products in two laboratories, at the University of 
California Los Angeles (UCLA) and QUT. A genomic sequence of 501 bp of the coding region 
of ANKK1 was amplified by PCR using the forward primer 5′-GCACGTGCCACCATACCC-3′ and 
the reverse primer 5′-TGCAGAGCAGTCAGGCTG -3′. A total of 5–10 ng of genomic DNA was 
amplified in a PCR master mix containing 0.2 μM of forward primer and 0.2 μM of reverse 
primer, 1x PCR buffer, 1.5 mM MgCl2, 200 μM dNTP and 1 unit of ‘Platinum Taq DNA 
Polymerase’ (Invitrogen) in a 25 μL volume. PCR amplification conditions were as follows: 
Step1, 94°C for 4 min; Step 2, 94°C for 30 s; Step 3, 68°C for 30 s andStep 4, 72°C for 30 s. 
Steps 2–4 were repeated in 40 cycles that were followed by 72°C for 3 min. The amplified 
PCR fragments were digested with TaqI restriction enzyme (New England Biolabs) and the 
digested fragments were visualized by agarose gel electrophoresis. The A1/A2(CT) genotype 
was revealed by three fragments: 
310bp, 180bp and 130bp. The A2/A2(CC) genotype was indicated by two fragments: 180bp 
and 130bp. The A1/A1(TT) genotype created an uncleaved 310bp fragment upon 
visualization, so all genotypes were readily distinguishable from each other. Any subjects 
with the A1/A1 and A1/A2 genotypes were considered to have the A1+ allelic status, while 
those with the A2/A2 homozygous genotype were considered to have the A1allelic status, 
consistent with previous studies (Noble, 2003) and a dominant model of inheritance. 
 Statistical analysis 
Chi-square test (Yates corrected) and Fisher’s exact test, where appropriate, were employed 
to compare differences in noncontinuous variables between A1+ and A1allelic groups. 
Analysis of variance (ANOVA) was used to compare differences among the various drug 
groups, with akathisia as a continuous variable. Similarly, one-way ANOVA was employed to 
examine differences in akathisia between the A1+ and A1allelic groups. A p-value of < .05 
was considered to be statistically significant. 
 
Results 
Genotyping results obtained from the two laboratories were crosschecked and found to be 
100% in agreement. Definite akathisia (a score ≥ 2 in our global clinical assessment of 
akathisia) was present in 16.8% of subjects whom were prescribed SGAs (n = 185) and in 
47.6% of those prescribed FGAs (n = 42) (χ2 [1] = 18.72; p < 0.0001). Seven patients were 
not assessed on this scale. The mean global clinical assessment score of those taking SGAs 
was 0.53 (SD = 0.87). Those prescribed FGAs had a higher mean score, of 1.29 (SD = 1.00). 
ANOVA revealed significantly higher global clinical assessment of akathisia scores in those 
patients prescribed FGAs, as compared to those taking SGAs (F [1,225] =24.64; p < 0.0001). 
Over the entire sample, A1+ participants (n =102) had higher scores on the global clinical 
assessment of akathisia than the A1participants (n = 125) (F [1,225] = 5.58, p = 0.011). 
Genotype data were missing in seven participants. A1+ individuals (n = 83) who were 
administered SGAs had higher global clinical assessment of akathisia scores (mean = 0.71; 
SD = 0.98) than A1participants administered the same class of medication (mean = 0.38; SD 
= 0.73 (n = 102) (F [1,183] = 6.790, p = 0.01); however, among those taking FGAs, the global 
clinical assessment of akathisia scores on the BARS were not significantly different in A1+ (n 
= 19) and A1(n = 23) patients (mean = 1.42 A1+ compared to A1= 1.17) (F [1, 40] = 0.64; p = 
0.430). Table 1 displays the results of global clinical assessment of akathisia on the BARS, as 
related to DRD2 allelic status. 
Of the patients prescribed SGAs, 31 had definite akathisia (a score ≥ 2 for the global clinical 
assessment of akathisia). Twenty of these participants (64.5%) were found to be A1+ and 11 
(35.5%) were A1-. The A1+ group was over-represented (χ2 [1] = 5.82, p = 0.016). Definite 
akathisia occurred in 24.1% of A1+ patients whom were treated with SGAs, as compared to 
10.8% of the A1patients. When A1+ patients treated with SGAs (n = 83) were compared to 
all patients treated with FGAs (n = 42), akathisia occurred more frequently in the FGA group 
(χ2 [1] = 7.09; p = 0.008). In order to account for possible confounders, all A1+ patients in 
the entire sample (n = 102) were compared with all A1participants (n = 125). ANOVA was 
employed to compare the continuous variables of age, dosage of antipsychotic (CPZEK), 
milligrams of nicotine consumed daily, expired carbon monoxide concentration AUDIT 
scores, PANSS negative scale scores and the Trail Making Test, parts A and B. These 
comparisons revealed no significant differences between A1+ and A1participants. Chisquare 
statistics were also employed to compare categorical variables in A1+ and A1patient groups. 
There were no differences in gender, presence of binge drinking, proportion of current 
smokers, nor prevalence of life time illicit drug use between A1+ and A1participants. These 
results are listed in Table 2. 
 
Discussion 
In our study, the prevalence of akathisia in schizophrenic patients whom were prescribed 
either SGAs or FGAs was generally higher than was previously reported. Our results 
indicated that 16.8% of patients prescribed SGAs and 47.6% of patients prescribed FGAs 
exhibited akathisia. The previously-reported figures are approximately 24% for SGAs and 
13% for FGAs (Miller et al., 1998). The higher point prevalence of akathisia that we describe 
here may be due to our systematic examination and diagnostic assessment for akathisia, 
which may have detected a higher number of cases. In addition, our clinical sample 
contained 90 inpatients who were acutely unwell, so they may have been prescribed an 
increased dosage of antipsychotic medication, as a result, which also could have contributed 
to the increased prevalence of akathisia found in this sample. 
Akathisia was found more frequently in patients prescribed FGAs, than in those prescribed 
SGAs. Individuals carrying the A1 allele were over-represented among patients with clinical 
akathisia, as nearly one in four A1+ patients who were prescribed SGAs had akathisia. 
Recently, a controversy has developed regarding the advantages of SGAs compared to FGAs 
(Kendall, 2011; Girgis, 2011). SGAs were initially promoted as being free of extrapyramidal 
adverse effects (Leucht and Davis, 2011). The ability of these medications to produce an 
antipsychotic effect without producing EPS and their unique action as serotonin 2 (5-HT2) 
receptor antagonists provided the rationale for the drugs’ designation as ‘atypical.’ In 
addition, the majority of SGAs do not appear as likely as FGAs to induce increases in 
prolactin. Risperidone and amisulpride are exceptions to this rule (Young et al., 2004; Lee et 
al., 2012); however, single photon and positron emission studies show that all 
antipsychotics of both the first and second generation do antagonise DRD2 (Leucht and 
Davis, 2011). 
This study shows that patients who were prescribed SGAs experience akathisia less 
commonly than those taking typical medications; however, this comparative advantage of 
atypical drugs regarding EPS risk is diminished in the A1+ patients. Nearly one-quarter of 
A1+ patients who were treated with SGAs developed akathisia. In comparison, only one-
tenth of the A1patients exhibited akathisia, when treated with SGAs. The SGAs may confer a 
more significant benefit for A1patients. However, despite the fact that nearly one-quarter of 
A1+ patients who were prescribed an SGA had definite akathisia, the SGAs prescribed to A1+ 
patients were still significantly less likely to produce akathisia than were FGAs. These results 
confirmed previous studies, which found that Taq1A variants were not associated with an 
increased liability for akathisia, in patients treated with ‘typical’ agents (Kaiser et al., 2002; 
Wu et al., 2006). However, the number of patients (n = 43) who were prescribed FGAs in the 
present study was not sufficient to demonstrate whether or not akathisia is associated with 
the A1+ status in this group. 
A1+ subjects who were treated with serotonin specific reuptake inhibitors are also reported 
to have an increased risk for EPS (Hedenmalm, et al., 2006), which demonstrates that A1+ 
patients are at risk for akathisia across different drug groups. Furthermore, A1+ patients are 
at an increased risk for tardive dyskinesia (Chen, 1997). Increased serum prolactin is also 
found in A1+ patients who are treated with SGAs (Young et al., 2004; López-Rodríguez, 
2011), illustrating that individual genetically-determined differences in DRD2 Bmax are 
contributory factors to the serious adverse effects that are associated with SGAs. 
The increased occurrence of akathisia, tardive dyskinesia and hyperprolactinaemia in A1+ 
patients may have contributed to the current debate regarding the validity of previously-
stated differences between FGAs and SGAs. A recent editorial by Kendall (2011) suggests 
that there is little difference between SGAs and FGAs, so they should all should be grouped 
as ‘just plain antipsychotics.’ Debate in this area has been based on the premise that 
individuals with DSM-1V criteria schizophrenia are physiologically homogeneous. 
Interactions between medication and genetically determined differences in physiology 
(specifically dopamine receptor polymorphisms) have not been considered so far in 
effectiveness trials comparing FGAs with SGAs. The Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) by Lieberman et al. (2005) finds no differences in the 
incidence of akathisia between perphenazine and three different SGAs; however, the 
patients’TaqIA status was not ascertained. 
The present study was limited by its cross-sectional nature, although inter-rater reliability 
tests were conducted to ensure the accurate determination of akathisia. The genotyping 
system employed in this study was based on the restriction digest method, which was 
employed in two separate laboratories (at UCLA and QUT), but the results were identical in 
each case. A further limitation was the relatively small number of patients who were 
prescribed FGAs, so a larger study is required to demonstrate whether TaqIA is a risk factor 
for this group. Yet another limitation was the lack of investigation of two other putative 
functional polymorphisms (141C Ins/Del and Ser311Cys). As the minor allele frequency of 
the 141C Ins/Del is approximately 10% (Jönsson et al., 1999) and the minor allele frequency 
of the Ser311Cys is approximately 2% (Jönsson et al., 2003), a considerably larger study 
would be needed to ascertain whether or not these polymorphisms are also risk factors for 
akathisia. 
Future research should employ a prospective methodology to examine the effects of 
genotype on akathisia. Examination of other parkinsonian signs and symptoms should also 
be performed, as it is likely that reduced striatal D2 density would probably influence 
parkinsonian symptoms (e.g. tremor, rigity and akinesia) as much, if not more, than 
akathisia. Our current data suggest that future investigations should include an examination 
of DRD2/ANKK1 Taq1A genotypes as a possible confounder, when adverse effects of SGAs 
and FGAs are compared. The current data have provided further support to the notion that 
antipsychotic-induced DRD2 antagonism is greater in A1+ patients, placing them at an 
increased risk for both EPS and raised serum prolactin. If our findings are replicated, a 
reduced dosage of antipsychotic medication in A1+ patients may result in a decreased 
likelihood of experiencing these adverse effects. 
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